Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4613 - Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer


11 Sep 2017


Poster display session


Breast Cancer


Lorenzo Gerratana


Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362


L. Gerratana1, D. Basile1, S. Zago2, M.G. Vitale1, G. Pelizzari1, M. Bonotto1, C. Bozza1, M. Bartoletti1, V. Fanotto1, C. Lisanti1, M. Cinausero1, S. Barban1, M. Lera1, I. Venuti1, M. Mansutti3, A.M. Minisini3, G. Fasola3, F. Curcio2

Author affiliations

  • 1 School Of Medical Oncology, Department Of Medicine, University of Udine, 33100 - Udine/IT
  • 2 Clinical Pathology Institute, University Hospital of Udine, 33100 - Udine/IT
  • 3 Department Of Oncology, University Hospital of Udine, 33100 - Udine/IT


Abstract 4613


Immunity plays a pivotal role in cancer progression and prognosis. A high neutrophil-to-lymphocite ratio (NLR) or a low lymphocyte-to-monocyte ratio (LMR) are respectively associated with systemic inflammation and immune suppression and have been associated with a poor outcome. Aim of this study is to further investigate the interaction between the immune system and breast cancer (BC) through the NLR and LMR.


This retrospective study analyzed a consecutive cohort of 657 patients (pts) with a diagnosis of pT1 BC, without restrictions regarding lymph node status (T1BC), or metastatic BC (MBC) treated between 2004 and 2017 at the Department of Oncology of Udine (Italy). Differences in terms of NLR and LMR among the two cohorts and between clinico-pathological characteristics in the T1BC subgroup were explored through the Kruskal-Wallis test. The prognostic impact in terms of OS in the T1BC population was investigated through uni- and multivariate Cox regression.


Both NLR and LMR were significantly different between the T1BC and the MBC cohorts. In particular, pts with T1BC had a higher median LMR (3.9 vs 2.9; P = 0.0001) and lower NLR (2 vs 2.7; P = 0.0001). After stratification according to molecular profile, T1BC and MBC cohorts of Luminal B-like subtype were significantly different in terms of both LMR (4.2 vs 3; P = 0.0001) and NLR (2 vs 2.5; P = 0.0001). In triple negative subtype, the difference between TB1C and MBC was observed for NLR (1.9 vs 3.2; P = 0.0272) only. On the other hand, no differences between TB1C and MBC were highlighted for the other subtypes. When focusing on the clinico-pathological characteristics of the T1BC cohort, LMR was associated with progesterone receptor (PR) expression (P = 0.0261) and marginally with the estrogen receptor (ER) expression, while NLR with tumor diameter (P = 0.0240) and marginally with grading. Furthermore, among T1BC pts, NLR had no prognostic impact in terms of OS, while LMR was associated with a better outcome also when corrected for ER, PR and HER2 status (HR 0.44, 95%CI 0.28 - 0.71, P = 0.001).


These results suggest a role for systemic inflammation and immune-suppression in breast cancer, especially in the triple negative and luminal B-like subtypes.

Clinical trial identification

Legal entity responsible for the study

University of Udine




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.